Technology areas: Biotechnology & Pharmaceuticals • Semiconductors, Circuits & Optics
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 9 patents granted in the last 365 days
Pacific Biosciences of California Inc. has 4 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 4 examiners and 4 art units, indicating that each action follows a separate examination channel.
PETKOVSEK, DANIEL is the busiest examiner, with 1 pending action. Counsel should manage each response independently, while maintaining a consistent portfolio position on recurring technical or claim issues.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (25%) |
| §112 only | 1 (25%) |
| Multi-statute (no §101) | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PETKOVSEK, DANIEL | 1 | 83.6% | +9.5% |
| RILEY, JEZIA | 1 | 83.0% | +7.2% |
| LU, FRANK WEI MIN | 1 | 62.7% | +67.9% |
| LAFAVE, ELIZABETH ROSE | 1 | 64.4% | +43.2% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18773005 | MODIFIED NUCLEOTIDE REAGENTS | RILEY, JEZIA | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17923506 | COMPOSITIONS AND METHODS FOR MODIFYING POLYMERASE-NUCLEIC ACID COMPLEXES | LAFAVE, ELIZABETH ROSE | 15d |
| 18894221 | Illumination of Optical Analytical Devices | PETKOVSEK, DANIEL | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17923506 | COMPOSITIONS AND METHODS FOR MODIFYING POLYMERASE-NUCLEIC ACID COMPLEXES | LAFAVE, ELIZABETH ROSE | 15d |
| 18240199 | MODIFIED BIOTIN-BINDING PROTEINS FOR IMMOBILIZATION | LU, FRANK WEI MIN | — |
| Art Unit | Apps |
|---|---|
| 2874 | 1 |
| 1681 | 1 |
| 1683 | 1 |
| 1684 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18894221 | Illumination of Optical Analytical Devices | PETKOVSEK, DANIEL | 2874 | §103§112 | Non-Final OA | — | Pending | Sep 24, 2024 |
| 18773005 | MODIFIED NUCLEOTIDE REAGENTS | RILEY, JEZIA | 1681 | §102Other | Non-Final OA | — | Pending | Jul 15, 2024 |
| 18240199 | MODIFIED BIOTIN-BINDING PROTEINS FOR IMMOBILIZATION | LU, FRANK WEI MIN | 1683 | §112 | Non-Final OA | — | Pending | Aug 30, 2023 |
| 17923506 | COMPOSITIONS AND METHODS FOR MODIFYING POLYMERASE-NUCLEIC ACID COMPLEXES | LAFAVE, ELIZABETH ROSE | 1684 | §102§103 | Non-Final OA | 15d | Pending | Nov 04, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialPacific Biosciences of California Inc. has 4 pending office actions as of October 2026, spread across 4 art units and 4 examiners.
Daniel Petkovsek has the most, with 1 of Pacific Biosciences of California Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
